Embed Size (px)
Citation preview
Product News
260 CUTIS® WWW.CUTIS.COM
Product News
Effaclar Dermatological Acne SystemLa Roche-Posay Laboratoire Dermatologique intro-duces the Effaclar Dermatological Acne System, an over-the-counter system to cleanse, tone, and treat using 3 products: Effaclar Medicated Gel Cleanser, Effaclar Clarifying Solution, and Effaclar Duo. The system is designed to reduce acne with little to no dry-ing or irritation. The Effaclar Dermatological Acne System targets excess sebum, hyperkeratinization, and the main triggers of acne. It can be purchased at select physicians’ offices and pharmacies as well as online. For more information, visit www.laroche-posay.us.
Hydrate MoisturizersObagi Medical Products, Inc, introduces 2 moistur-izers that provide long-lasting hydration: Hydrate Facial Moisturizer and Hydrate Luxe. Hydrate Facial Moisturizer provides all-day moisture protection for every skin type with immediate and lasting effects on skin barrier function. Hydrate Luxe is engineered with biomimetic peptides to work overnight. It saturates skin with 8-hour moisture protection, and also promotes skin radiance. Both products are dispensed in derma-tology, plastic surgery, and other aesthetic physicians’ practices. For more information, visit www.obagi.com.
Stretch Mark CrèmeNatural skin care company derma e reveals Stretch Mark Crème to visibly diminish the look of stretch marks, as well as improve texture, color, and overall appearance. Stretch Mark Crème contains argan oil, cocoa butter, coconut oil, and shea butter to intensely condition skin to help increase elasticity and resiliency. It also contains vitamin E to promote self-healing and hyaluronic acid to attract and bind moisture to the skin. For more information, visit www.dermae.com.
TaclonexLEO Pharma Inc announces a new pediatric indication for Taclonex (calcipotriene 0.005%–betamethasone dipropionate 0.064%) Topical Suspension. Taclonex is a first-line, once-daily combination product indicated for treatment of both scalp and body psoriasis in adults 18 years and older for up to 8 weeks. It is now also indi-cated for the treatment of plaque psoriasis of the scalp in patients aged 12 to 17 years for the same period. For more information, visit www.taclonex.com. If you would like your product included in Product News, please e-mail a press release to the Editorial Office at [email protected].
Copyright Cutis 2014. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.
CUTIS Do not c
opy
